• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Inogen Inc (Amendment)

    2/14/23 9:00:08 AM ET
    $INGN
    Industrial Specialties
    Health Care
    Get the next $INGN alert in real time by email
    SC 13G/A 1 fp0081791-1_sc13ga.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (AMENDMENT NO. 12)*

     

    Inogen, Inc.

     

    (Name of Issuer)

     

    Common Stock, Par Value $0.001

     

    (Title of Class of Securities)

     

    45780L104

     

    (CUSIP Number)

     

    Eddie C. Brown

    Brown Capital Management, LLC

    1201 N. Calvert Street

    Baltimore, MD 21202

    (410) 837-3234

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    December 31, 2022

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [x] Rule 13d-1(b) 

    [  ] Rule 13d-1(c) 

    [  ] Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

    CUSIP No. 45780L104   13G   Page 2 of 5 Pages

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Brown Capital Management, LLC 

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 

    (see instructions)

     

    (a) [  ]

    (b) [  ] 

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    State of Maryland 

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    680,106 

    6.

    SHARED VOTING POWER

     

    None 

    7.

    SOLE DISPOSITIVE POWER

     

    1,715,188 

    8.

    SHARED DISPOSITIVE POWER

     

    None 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,715,188 

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 

    (see instructions) [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.48% 

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA 

     

     

     

    CUSIP No. 45780L104   13G   Page 3 of 5 Pages

     

    Item 1. (a)

    Name of Issuer 

    Inogen, Inc. 

         
      (b)

    Address of Issuer’s Principal Executive Offices 

    301 Coromar Drive 

    Goleta, California 93117 

     

    Item 2. (a)

    Name of Person Filing 

    Brown Capital Management, LLC 

         
      (b)

    Address of the Principal Office or, if none, residence 

    1201 N. Calvert Street 

    Baltimore, MD 21202 

         
      (c)

    Citizenship 

    Brown Capital Management, LLC is a Maryland Limited Liability Company 

         
      (d)

    Title of Class of Securities 

    Common Stock, Par Value $0.001 

         
      (e)

    CUSIP Number 

    45780L104 

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) [  ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) [  ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) [  ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [x] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) [  ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) [  ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) [  ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) [  ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [  ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

    CUSIP No. 45780L104   13G   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 1,715,188
    (b) Percent of class: 7.48%
    (c) Number of shares as to which the person has:  
      (i) Sole power to vote or to direct the vote: 680,106
      (ii) Shared power to vote or to direct the vote: None
      (iii) Sole power to dispose or to direct the disposition of: 1,715,188
      (iv) Shared power to dispose or to direct the disposition of: None

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    All of the shares of Common Stock set forth in Item 4 are owned by various investment advisory clients of Brown Capital Management, LLC, which is deemed to be a beneficial owner of those shares pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, due to its discretionary power to make investment decisions over such shares for its clients and/or its ability to vote such shares. In all cases, persons other than Brown Capital Management, LLC have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of the shares.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable 

     

     

    CUSIP No. 45780L104   13G   Page 5 of 5 Pages

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Brown Capital Management, LLC  
           
      By: /s/ Eddie C. Brown  
      Name: Eddie C. Brown  
      Title: CEO  
           
      Date: February 14, 2023  

    Get the next $INGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INGN

    DatePrice TargetRatingAnalyst
    6/16/2025$14.00Buy
    B. Riley Securities
    5/22/2025$12.00Hold → Buy
    Needham
    2/15/2024Mkt Perform → Outperform
    William Blair
    8/8/2023$15.00 → $8.00Overweight → Neutral
    JP Morgan
    7/14/2023Buy → Hold
    Needham
    1/17/2023Outperform → Mkt Perform
    William Blair
    12/9/2021$47.00Hold → Buy
    Needham
    11/8/2021$70.00 → $40.00Hold
    Stifel
    More analyst ratings

    $INGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inogen Announces Second Quarter 2025 Financial Results

    Delivered strong top-line results; raising full year 2025 revenue expectations Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2025. Recent Highlights Achieved second quarter 2025 revenue of $92.3 million, a year-over-year increase of 4.0%, marking the sixth consecutive quarter of mid-single-digit percentage growth. Reported GAAP net loss of $4.2 million and adjusted net loss of $0.7 million. Delivered adjusted EBITDA of $2.1 million, the second consecutive quarter of positive adjusted EBITDA. Generated $4.4 million in operating

    8/7/25 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2025 financial results after the market closes on Thursday, August 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen I

    7/17/25 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy

    Inogen, Inc. (Nasdaq: INGN), a leading medical technology company specializing in innovative respiratory products for homecare use, today announced the launch of VoxiTM 5, a new stationary oxygen concentrator (SOC) designed to enhance access to high-quality oxygen therapy for long-term care patients in the United States. As the latest addition to Inogen's product portfolio, Voxi 5 augments the company's line of portable oxygen concentrators, significantly expanding the market potential while leveraging existing sales channels. The Voxi 5 stationary oxygen concentrator combines affordability with durability, setting a new standard in oxygen therapy Developed in collaboration with Yuwell

    6/23/25 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    SEC Filings

    View All

    SEC Form 10-Q filed by Inogen Inc

    10-Q - Inogen Inc (0001294133) (Filer)

    8/8/25 4:11:21 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Inogen Inc (0001294133) (Filer)

    8/7/25 4:24:22 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Inc filed SEC Form 8-K: Leadership Update

    8-K - Inogen Inc (0001294133) (Filer)

    7/29/25 4:06:11 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:42:36 PM ET
    $INGN
    Industrial Specialties
    Health Care

    CEO and President Smith Kevin Raymond Merrill was granted 55,475 shares, converted options into 28,333 shares, covered exercise/tax liability with 39,797 shares and bought $100,245 worth of shares (11,709 units at $8.56), increasing direct ownership by 383% to 70,274 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:41:11 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Inogen with a new price target

    B. Riley Securities initiated coverage of Inogen with a rating of Buy and set a new price target of $14.00

    6/16/25 7:50:27 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen upgraded by Needham with a new price target

    Needham upgraded Inogen from Hold to Buy and set a new price target of $12.00

    5/22/25 8:16:14 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen upgraded by William Blair

    William Blair upgraded Inogen from Mkt Perform to Outperform

    2/15/24 6:28:38 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Wright Mary E claimed ownership of 12,180 shares (SEC Form 3)

    3 - Inogen Inc (0001294133) (Issuer)

    8/7/25 4:32:10 PM ET
    $INGN
    Industrial Specialties
    Health Care

    New insider Yi Boyer Jennifer M claimed ownership of 13,509 shares (SEC Form 3)

    3 - Inogen Inc (0001294133) (Issuer)

    8/7/25 4:31:08 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Director Boehnlein Glenn S was granted 30,612 shares, increasing direct ownership by 66% to 76,885 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    5/19/25 8:53:23 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Leadership Updates

    Live Leadership Updates

    View All

    Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    2/3/25 4:00:00 PM ET
    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

    MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

    11/7/24 4:04:00 PM ET
    $INGN
    $SGHT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Inogen Appoints Eric Pauls as Vice President of Sales, North America

    Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Eric Pauls as Vice President of Sales, North America, effective September 3, 2024. Mr. Pauls joins Inogen from RQM+, where he served as Chief Customer Officer. Kevin Smith, President and Chief Executive Officer of Inogen said, "We are excited to welcome Eric to the Inogen team. With over 20 years of experience driving growth and leading high-performing teams in the respiratory care business, his leadership will be instrumental as we expand our product offerings and solutions for patients with respiratory conditions in the Uni

    9/5/24 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Financials

    Live finance-specific insights

    View All

    Inogen Announces Second Quarter 2025 Financial Results

    Delivered strong top-line results; raising full year 2025 revenue expectations Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2025. Recent Highlights Achieved second quarter 2025 revenue of $92.3 million, a year-over-year increase of 4.0%, marking the sixth consecutive quarter of mid-single-digit percentage growth. Reported GAAP net loss of $4.2 million and adjusted net loss of $0.7 million. Delivered adjusted EBITDA of $2.1 million, the second consecutive quarter of positive adjusted EBITDA. Generated $4.4 million in operating

    8/7/25 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2025 financial results after the market closes on Thursday, August 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen I

    7/17/25 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces First Quarter 2025 Financial Results

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p

    5/7/25 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inogen Inc

    SC 13G/A - Inogen Inc (0001294133) (Subject)

    11/14/24 11:12:09 AM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Inogen Inc

    SC 13G - Inogen Inc (0001294133) (Subject)

    4/23/24 8:25:34 PM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Inogen Inc (Amendment)

    SC 13G/A - Inogen Inc (0001294133) (Subject)

    2/14/24 4:00:17 PM ET
    $INGN
    Industrial Specialties
    Health Care